KDC-MN-161 – Kodiac biolabs

Plain-language summaryIntrigue 78 / 100

Brexanolone, sold as Zulresso, is recombinant allopregnanolone administered as a 60-hour IV infusion for postpartum depression. The first FDA-approved postpartum depression specific treatment (2019). Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

51/100

FDA-approved neurosteroid for PPD with real evidence but limited bench access and zuranolone superseding it

Look, the clinical story here is genuinely compelling. Brexanolone was the first FDA-approved neuroactive steroid targeting postpartum depression, and the phase 3 data from Sage’s pivotal trials (BRX-300 and BRX-301) showed rapid symptom resolution within 24-48 hours of infusion start. For a field accustomed to antidepressants taking weeks, thats actually striking. The mechanism is real: brexanolone acts as a positive allosteric modulator at GABA-A receptors, with particular affinity for extrasynaptic delta-subunit-containing receptors that benzodiazepines largely miss.

That delta-subunit selectivity is the interesting part. Classic benzo pharmacology hits synaptic gamma2-containing receptors; the extrasynaptic pool is tonically active and responds to neurosteroids like allopregnanolone specifically. The working hypothesis behind the PPD indication is that parturition triggers a rapid collapse of neurosteroid tone, and that reconstituting it via prolonged IV infusion can reset the system quickly. It’s a coherent, testable model, and the clinical data supports it in at least this one population.

The problem for research utility is everything around the pharmacology. The compound itself is endogenous allopregnanolone; brexanolone is the formulation, not a new chemical entity. Achieving sustained plasma concentrations required a 60-hour inpatient infusion with continuous monitoring, which is exactly why the FDA required a REMS. That REMS means restricted distribution, certified inpatient settings only, and a monitoring protocol that would be deeply inconvenient for most bench programs. We’re not rating clinical accessibility, but bench value is part of the score, and a compound you cant source without navigating REMS bureaucracy has real limits as a probe.

Honestly, the arrival of zuranolone changes the picture considerably. Zuranolone is the same neurosteroid pharmacology in an oral formulation with a much cleaner access profile for investigators interested in the delta-subunit story. If you want to study extrasynaptic GABA-A modulation by neuroactive steroids in 2026, zuranolone is the practical choice. Brexanolone’s value proposition has narrowed to historical reference standard and approved clinical agent rather than active research tool.

What we like: evidence quality is high, the mechanism is genuinely more nuanced than generic GABAergic pharmacology, and the PPD indication opened a real research window on peripartum neurosteroid dynamics that remains active. What we dont like: the IV REMS delivery model makes it nearly inaccessible as a bench compound, the chemical novelty is essentially zero since this is an endogenous molecule, and zuranolone largely supersedes it for the research questions that matter going forward. The clinical chapter here is closed and well-written; the research chapter probably isn’t brexanolone’s to write.

Novelty: 40
Mechanism promise: 55
In-category differentiation: 40
Evidence quality: 72
Translational signal: 70
Research bench value: 28

Rationale Brexanolone scores well on evidence and translational signal (FDA-approved, phase 3 RCTs, rapid PPD symptom resolution) but is penalized heavily on bench value due to IV-only REMS delivery, and on novelty and differentiation because the chemical entity is endogenous allopregnanolone and zuranolone now covers the same pharmacology orally.

Synthetic allopregnanolone (IV)

Synthetic allopregnanolone formulated for IV administration, FDA-approved as Zulresso for postpartum depression.

Abstract

Brexanolone (Zulresso; SAGE-547; CAS 516-54-1, same as endogenous allopregnanolone) is a synthetic preparation of allopregnanolone formulated for 60-hour intravenous infusion, developed by Sage Therapeutics and approved by the FDA in 2019 for postpartum depression. The compound is identical in structure to endogenous allopregnanolone; the development innovation was the formulation enabling sustained therapeutic plasma concentrations through prolonged IV infusion. Mechanism is GABA-A receptor positive allosteric modulation. Schedule IV. Restricted distribution program (REMS) due to risk of excessive sedation and loss of consciousness. The closely related zuranolone provides oral dosing with similar pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-161Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-161

Brexanolone

Abstract

Read the full monograph